Evidence map›Paper›PMID 41402361›Full record

ArticleScientific reports2025

A retrospective cohort study on the association between allergic rhinitis, sublingual immunotherapy, and COVID-19 symptomatology.

Ying-Ying Zhang, Mei-Ping Lu, Yan-Bing Chen, Lin Jiang, Qian Lyu, Yuan Tang, Min Zhang, Lei Cheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ying-Ying ZhangDepartment of Otorhinolaryngology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.
Mei-Ping LuDepartment of Otorhinolaryngology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.
Yan-Bing ChenDepartment of Otorhinolaryngology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.
Lin JiangDepartment of Otorhinolaryngology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.
Qian LyuDepartment of Allergology & Clinical Allergy Center, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.
Yuan TangDepartment of Allergology & Clinical Allergy Center, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.
Min ZhangDepartment of Otorhinolaryngology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China. dr.minzhang@njmu.edu.cn.
Lei ChengDepartment of Otorhinolaryngology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China. chenglei@jsph.org.cn.

Funding

Jiangsu Province Capability Improvement Project through Science, Technology and Education of China JSDW202203
6 · The paper itself

Abstract

The impacts of allergic rhinitis (AR) and allergen-specific sublingual immunotherapy (SLIT) on coronavirus disease 2019 (COVID-19) have not been fully understood. Therefore, the aim of this study was to investigate the effects of AR and SLIT on symptoms of COVID-19 within one month after Chinese authorities adjusted their COVID-19 response measures. The study enrolled 1368 participants, including 746 AR patients and 622 controls without allergic diseases. SLIT was administered to 122 infected AR patients (AR with SLIT group), while it was not administered to the other 483 infected AR patients (AR without SLIT group). Patients’ outcomes were compared after propensity score matching (PSM). The data showed that AR played a dual role in COVID-19, acting as both a protective factor against respiratory symptoms and a risk factor increasing the likelihood of olfactory/gustatory dysfunctions and fever, compared to non-allergic individuals. Conversely, AR patients treated with SLIT presented a higher risk of respiratory symptoms but a lower risk of fever. SLIT did not influence the risk of olfactory/gustatory dysfunctions. Thus, respiratory symptoms should be considered when deciding whether to apply SLIT in AR patients with COVID-19. Additionally, the risk of fever should also be taken into account.

Indexed as

COVID-19Rhinitis, AllergicSublingual ImmunotherapyAdultFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsSARS-CoV-2Allergic rhinitisCOVID-19Olfaction disordersRespiratory symptomsSARS-CoV-2Sublingual immunotherapy

Identifiers

PMID41402361
PMCPMC12808318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.